Great News

JULY 15, 2016 Knight Acquires Minor Stake in Pediapharm MONTREAL, QUEBEC--(Marketwired - July 15, 2016) - Knight Therapeutics Inc. ("Knight") (TSX:GUD) today announced that it has acquired 11,470,920 common shares (the "Shares") of Pediapharm Inc. ("Pediapharm") in exchange for 221,126 common shares of Knight and 221,126 four-year warrants of Knight, with an exercise price of $10.00. The Shares represent approximately 15.8% of the outstsanding common shares of Pediapharm. Knight owns an aggregate of 13,413,420 common shares of Pediapharm representing approximately 18.5% of the outstanding common shares of Pediapharm. The closing price on the TSX on the last trading day immediately preceding the purchase of the Shares was $8.35, representing an aggregate dollar value in respect of the Knight shares issued of $1,846,402. Using the closing price, the Black Scholes model renders a value of $2.82 for each warrant issued, or $623,575 in the aggregate. Knight holds 757,500 warrants, which are convertible into 757,500 common shares of Pediapharm at an exercise price of $0.33 per common share at any time until March 30, 2019. Should Knight exercise the warrant, Knight would acquire an additional, 757,500 common shares of Pediapharm, representing 1.0% of the issued and outstanding of common shares of Pediapharm, after taking effect of the exercise of the warrant. Knight acquired the Shares for investment purposes. Knight may in the future purchase or sell Shares of Pediapharm or otherwise trade in securities of or engage in other transactions with respect to Pediapharm depending on a number of factors, including but not limited to, Pediapharm's financial position, the price levels of the common shares of Pediapharm, conditions in the securities markets and general economic and industry conditions, Pediapharm's business or financial condition, and other factors and conditions Knight deems appropriate.

PDP.V (Mkap 12 M€) 6 Produkte am Markt + 4 warten auf Zulassung | wallstreet-online.de - Vollständige Diskussion unter:
http://www.wallstreet-online.de/diskussion/1210274-371-380/pdp-v-mkap-12-m-6-produkte-markt-4-warten-zulassung#neuster_beitrag

2 Approvals around the corner = 300-500% upside Potential here

Rupafin approval in August will push this unknown low float gem 100% and higher .Another Approval (Otixal) is expected in November . Market Cap of $10.8 Million is ridiculous for this great Company especially when the Cash blance is over $7 Million .Get some before they get the Approval .GL



Pediapharm (PDP.V)

Market Cap: c$10.8 Million
Cash: c$7.5 Million
Price 0.15

Presentation
http://pedia-pharm.com/wp-content/themes/ifeature-tpl/PDF/Pediapharm-Corporate-Presentation-MARCH-2016-v4-WEBSITE-PDF.pdf

2 Health Canada approval:Rupafin(Aug-Sept 2016) and Otixal (Nov-Dec 2016)


Rupatadine’s estimated launch is now estimated to be in the period of July-September 2016 vs October-December 2016 as previously stated due to the fact the Company now estimates it will receive Health Canada’s approval by August 2016.

PRODUCT INDICATION MARKET SIZE (CDN $) EST. ANNUAL PEAK SALES (CDN$) EST. LAUNCH DATE

Rupatadine(Rupafin) Antihistamine (RX Indication) 120M 6M Q-3 2016

Cetraxal-Plus (Otixal) Ear Infection, Swimmer’s Ear 25M 4M Q-4 2016

The Company is close to profitability and with 5 more products to enter the Market within next 12 Months and plus more inlicensing of Products ,this Company will be a cash cow .

Pediapharma has a Marketcap of just C$22 Million thats a big joke for such great Company but you need experience to realize the big potential here .

PDP: 14M curr peak (not actual) sales + 35M peak sales for new launches.
Why is this a lifetime oppty???

This Undiscovered Company has 6 Drugs on Market and 5 under review by Health Canada . The Game Changer for Pediapharm is Easyhaler which expected to approved before year end .Another reason to own the Stock is the upcoming US-Partnership for Naproxen which also expected before year end . This Stock is a Lifetime Opportunity .


Pediapharm (PDP)

MarketCap: C$ 22.2 Millionen
Cash: $5.5 Millionen

Price: $0.31


Nice Summary (Fact Sheet)
http://www.pedia-pharm.com/wp-content/themes/ifeature-tpl/PDF/PDP_Fact_sheet_oct_26_2015.pdf




Pediapharm has submitted its reconsideration package to Health Canada regarding Easyhaler Budesonide. The Company’s objective remains to obtain a marketing approval by the end of 2015.


Furthermore, before the end of 2015, the Company intends to sign an agreement with a US commercial partner for the selling and marketing of its first product acquisition in the US; namely the Pediapharm Naproxen Suspension. Pediapharm believes that with this agreement, the Company will reach profitability more rapidly.